These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27297359)

  • 1. Recent advances in the development of sphingosine kinase inhibitors.
    Pitman MR; Costabile M; Pitson SM
    Cell Signal; 2016 Sep; 28(9):1349-1363. PubMed ID: 27297359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of the sphingosine kinase pathway as potential therapeutics.
    Pitman MR; Pitson SM
    Curr Cancer Drug Targets; 2010 Jun; 10(4):354-67. PubMed ID: 20370685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles, regulation and inhibitors of sphingosine kinase 2.
    Neubauer HA; Pitson SM
    FEBS J; 2013 Nov; 280(21):5317-36. PubMed ID: 23638983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances.
    Pyne S; Adams DR; Pyne NJ
    Prog Lipid Res; 2016 Apr; 62():93-106. PubMed ID: 26970273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties.
    Pitman MR; Powell JA; Coolen C; Moretti PA; Zebol JR; Pham DH; Finnie JW; Don AS; Ebert LM; Bonder CS; Gliddon BL; Pitson SM
    Oncotarget; 2015 Mar; 6(9):7065-83. PubMed ID: 25788259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.
    Orr Gandy KA; Obeid LM
    Biochim Biophys Acta; 2013 Jan; 1831(1):157-66. PubMed ID: 22801037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine kinase 1 as an anticancer therapeutic target.
    Gao Y; Gao F; Chen K; Tian ML; Zhao DL
    Drug Des Devel Ther; 2015; 9():3239-45. PubMed ID: 26150697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases.
    Gao P; Peterson YK; Smith RA; Smith CD
    PLoS One; 2012; 7(9):e44543. PubMed ID: 22970244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
    Selvam SP; Ogretmen B
    Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of sphingosine kinase inhibitors.
    French KJ; Upson JJ; Keller SN; Zhuang Y; Yun JK; Smith CD
    J Pharmacol Exp Ther; 2006 Aug; 318(2):596-603. PubMed ID: 16632640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-function analysis of lipid substrates and inhibitors of sphingosine kinases.
    Adams DR; Pyne S; Pyne NJ
    Cell Signal; 2020 Dec; 76():109806. PubMed ID: 33035646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingosine kinase 1 in cancer.
    Heffernan-Stroud LA; Obeid LM
    Adv Cancer Res; 2013; 117():201-35. PubMed ID: 23290781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase.
    Pitson SM; Moretti PA; Zebol JR; Xia P; Gamble JR; Vadas MA; D'Andrea RJ; Wattenberg BW
    J Biol Chem; 2000 Oct; 275(43):33945-50. PubMed ID: 10944534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy.
    Yaghobian D; Don AS; Yaghobian S; Chen X; Pollock CA; Saad S
    Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):56-66. PubMed ID: 26414003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
    Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
    Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.
    Paugh SW; Paugh BS; Rahmani M; Kapitonov D; Almenara JA; Kordula T; Milstien S; Adams JK; Zipkin RE; Grant S; Spiegel S
    Blood; 2008 Aug; 112(4):1382-91. PubMed ID: 18511810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.
    Edmonds Y; Milstien S; Spiegel S
    Pharmacol Ther; 2011 Dec; 132(3):352-60. PubMed ID: 21906625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short Periods of Hypoxia Upregulate Sphingosine Kinase 1 and Increase Vasodilation of Arteries to Sphingosine 1-Phosphate (S1P) via S1P
    Alganga H; Almabrouk TAM; Katwan OJ; Daly CJ; Pyne S; Pyne NJ; Kennedy S
    J Pharmacol Exp Ther; 2019 Oct; 371(1):63-74. PubMed ID: 31371480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases.
    Wong L; Tan SS; Lam Y; Melendez AJ
    J Med Chem; 2009 Jun; 52(12):3618-26. PubMed ID: 19469544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel sphingosine kinase 1 inhibitors.
    Xiang Y; Asmussen G; Booker M; Hirth B; Kane JL; Liao J; Noson KD; Yee C
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6119-21. PubMed ID: 19800228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.